Amersham, the UK imaging and biotechnology group, was advised by Freshfields Bruckhaus Deringer in relation to a share for share offer, which will value the company at approximately £5.7bn.
Freshfields is advising Amersham on the US securities law and US antitrust aspects of the transaction, as well as the UK/European legal and antitrust aspects. Completion of the agreement is subject to a vote by Amersham shareholders.
“It has been very exciting working on a share exchange acquisition of this magnitude,” said Corporate Partner Will Lawes. “Freshfields has advised Amersham for many years and have worked closely with their executive team over the past decade. We look forward to continuing being a part of the Amersham story in the future.”
The Freshfields team was led by Corporate Partner Will Lawes, Senior Partner Anthony Salz, along with corporate partners James Wood and corporate associates Madelaine McTernan and Robin Marchant, in addition to partners Nicholas Spearing (ACT), Paul Yde (ACT, Washington), Sarah Falk (Tax), Jocelyn Mitchell (EPB) and senior associates Andrew Taggart (EPB), Helen Lethaby (Tax) and Diarmuid Ryan (ACT).
